NVDA

176.11

+3.08%↑

AVGO.US

313.1

+3.29%↑

ORCL

146.6

+2.65%↑

MU

367.41

+12.77%↑

CSCO

78.59

+1.26%↑

NVDA

176.11

+3.08%↑

AVGO.US

313.1

+3.29%↑

ORCL

146.6

+2.65%↑

MU

367.41

+12.77%↑

CSCO

78.59

+1.26%↑

NVDA

176.11

+3.08%↑

AVGO.US

313.1

+3.29%↑

ORCL

146.6

+2.65%↑

MU

367.41

+12.77%↑

CSCO

78.59

+1.26%↑

NVDA

176.11

+3.08%↑

AVGO.US

313.1

+3.29%↑

ORCL

146.6

+2.65%↑

MU

367.41

+12.77%↑

CSCO

78.59

+1.26%↑

NVDA

176.11

+3.08%↑

AVGO.US

313.1

+3.29%↑

ORCL

146.6

+2.65%↑

MU

367.41

+12.77%↑

CSCO

78.59

+1.26%↑

Search

Fortive Corp

Abierto

SectorTecnología

55.75 2.24

Resumen

Variación precio

24h

Actual

Mínimo

54.2

Máximo

56.1

Métricas clave

By Trading Economics

Ingresos

137M

192M

Ventas

95M

1.1B

P/B

Media del Sector

34.837

81.314

Rentabilidad por dividendo

0.51

Margen de beneficios

17.06

Empleados

10,000

EBITDA

11M

225M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+9.33% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.51%

2.43%

Próximas Ganancias

30 abr 2026

Fecha Próximo Dividendo

26 jun 2026

Próxima Fecha de Ex Dividendo

29 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-576M

18B

Apertura anterior

53.51

Cierre anterior

55.75

Noticias sobre sentimiento de mercado

By Acuity

31%

69%

85 / 375 Clasificación en Technology

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Fortive Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

31 mar 2026, 23:31 UTC

Acciones populares

Stocks to Watch: Nike, RH, NCino

31 mar 2026, 22:35 UTC

Ganancias

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 abr 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar 2026, 23:50 UTC

Adquisiciones, fusiones, absorciones

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar 2026, 23:33 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar 2026, 23:21 UTC

Ganancias

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar 2026, 23:14 UTC

Charlas de Mercado
Ganancias

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar 2026, 23:12 UTC

Charlas de Mercado

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar 2026, 22:36 UTC

Ganancias

China Vanke 2025 Loss Widens >000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar 2026, 22:36 UTC

Ganancias

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar 2026, 21:46 UTC

Adquisiciones, fusiones, absorciones

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar 2026, 21:36 UTC

Charlas de Mercado

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar 2026, 21:35 UTC

Ganancias

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Ganancias

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Ganancias

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 21:33 UTC

Ganancias

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar 2026, 21:32 UTC

Ganancias

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar 2026, 21:28 UTC

Ganancias

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar 2026, 21:26 UTC

Ganancias

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar 2026, 21:25 UTC

Ganancias

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar 2026, 21:24 UTC

Charlas de Mercado
Ganancias

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar 2026, 21:22 UTC

Ganancias

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar 2026, 21:22 UTC

Ganancias

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar 2026, 21:21 UTC

Ganancias

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar 2026, 21:20 UTC

Ganancias

Nike CEO: Converse Remains Important to Portfolio

Comparación entre iguales

Cambio de precio

Fortive Corp previsión

Precio Objetivo

By TipRanks

9.33% repunte

Estimación a 12 Meses

Media 60.44 USD  9.33%

Máximo 65 USD

Mínimo 51 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Fortive Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

10 ratings

2

Comprar

6

Mantener

2

Vender

Puntuación técnica

By Trading Central

66.84 / 69.85Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

85 / 375 Clasificación en Tecnología

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Fortive Corp

Fortive Corporation designs, develops, manufactures, and services professional and engineered products, software, and services in the United States, China, and internationally. It operates in three segments: Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. The Intelligent Operating Solutions segment provides advanced instrumentation, software, and services, including electrical test and measurement, facility and asset lifecycle software applications, and connected worker safety and compliance solutions for manufacturing, process industries, healthcare, utilities and power, communications and electronics, and other industries. This segment markets its products and services under the ACCRUENT, FLUKE, GORDIAN, INDUSTRIAL SCIENTIFIC, INTELEX, PRUFTECHNIK, and SERVICECHANNEL brands. The Precision Technologies segment offers electrical test and measurement, sensing and material technologies for industrial, power and energy, automotive, medical equipment, food and beverage, aerospace and defense, semiconductor, and other general industries under the ANDERSON-NEGELE, GEMS, SETRA, HENGSTLER-DYNAPAR, QUALITROL, PACIFIC SCIENTIFIC, KEITHLEY, and TEKTRONIX brand names. The Advanced Healthcare Solutions segment provides critical workflow solutions comprising instrument sterilization, instrument tracking, design and manufacture of cell therapy equipment, biomedical test tools, radiation detection and safety monitoring, and end-to-end clinical productivity software and solutions under the ASP, CENSIS, CENSITRAC, EVOTECH, FLUKE BIOMEDICAL, INVETECH, LANDAUER, PROVATION, RAYSAFE, and STERRAD brands. Fortive Corporation was incorporated in 2015 and is headquartered in Everett, Washington.
help-icon Live chat